Supramolecular cyclodextrin nanocarriers for chemo- and gene therapy towards the effective treatment of drug resistant cancers.

Abstract

A tumor active targeting β-cyclodextrin based nanocarrier β-NC-OEI-SS-FA was designed by the modification of star shaped cationic derivatives β-NC-OEI with folic acid through a disulfide bond, to co-deliver chemotherapeutic paclitaxel and the Nur77 gene for overcoming Bcl-2 mediated non-pump resistance by an "enemy to friend" strategy for potential drug resistant cancer therapy.

• Authors: Xiaohong Chen, Ying-Kun Qiu, Cally Owh, Xian Jun Loh, Yun-Long Wu
• Journal: Nanoscale (Nanoscale) Vol. 8 Issue 45 Pg. 18876-18881 (Dec 07 2016) ISSN: 2040-3372 [Electronic] England
• PMID: 27819368 (Publication Type: Journal Article)

Chemical References

• BCL2 protein, human
• Cyclodextrins
• Nuclear Receptor Subfamily 4, Group A, Member 1
• Proto-Oncogene Proteins c-bcl-2
• Folic Acid
• Paclitaxel

Topics

• Animals
• Cyclodextrins (chemistry)
• Drug Delivery Systems
• Drug Resistance, Neoplasm
• Folic Acid (chemistry)
• Genetic Therapy
• HeLa Cells
• Hep G2 Cells
• Humans
• Mice
• Molecular Structure
• Nanoparticles
• Neoplasms (therapy)
• Nuclear Receptor Subfamily 4, Group A, Member 1 (genetics)
• Paclitaxel (administration & dosage)
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• Transfection
• Xenograft Model Antitumor Assays